


# RADIATION THERAPY IN PROSTATE CANCER SYMPOSIUM



**DEPARTMENT OF RADIATION ONCOLOGY**  
MEDICAL CENTER - UNIVERSITY OF FREIBURG, GERMANY

## WELCOME

Dear colleagues,

We are pleased to welcome you to the Radiation Therapy in Prostate Cancer - Symposium in Freiburg, Germany.

Diagnostics and treatment in prostate cancer have experienced tremendous changes, and new therapeutic options have emerged in recent years. Focusing on these advances, our symposium serves as a platform to discuss current trends and state-of-the-art techniques in the radiotherapy of primary prostate cancer. Additionally, experts will share insights into modern approaches in the management of recurrent and metastatic disease. The strength of interdisciplinary patient care will be highlighted by our colleagues and collaborators from Urology, Nuclear Medicine, Radiology and Pathology, who will present updates on new hormonal agents, systemic treatment options, radioligand therapy, and diagnostic options. Furthermore, we will explore opportunities provided by artificial intelligence and how they allow physicians to further improve and personalize treatments.

Join the multidisciplinary panel of national and international specialists and key opinion leaders and participate in lively discussions, These new insights will help to improve care for our patients everywhere.


**Anca-Ligia Grosu**, MD, FACR, Professor and Chair, Department of Radiation Oncology

**Simon Spohn**, MD, Department of Radiation Oncology

# PLUVICTO®\*

## beim mCRPC:

### Verlängerte signifikant das Gesamtüberleben<sup>1,2</sup>



Die ERSTE zugelassene **PSMA-zielgerichtete Radioligandentherapie (RLT)**, die bei PSMA-positiven mCRPC-Patienten im Rahmen der VISION-Studie das Überleben signifikant verlängerte und die Lebensqualität länger aufrechterhielt als SoC (Standard of Care)<sup>1-3</sup>

\* Pluvicto® wird in Kombination mit Androgendepressionstherapie (ADT) mit oder ohne Inhibition des Androgenrezeptor-(AR-)Signalwegs angewendet zur Behandlung von erwachsenen Patienten mit progredientem PSMA-positivem mCRPC, die zuvor mittels Inhibition des AR-Signalwegs und taxanbasierter Chemotherapie behandelt wurden.

#### Referenzen:

1. Aktuelle Fachinformation Pluvicto®.
2. Sartor O et al. N Engl J Med. 2021; 385(12): 1091 – 1103.
3. Sartor O et al. N Engl J Med. 2021 Sep; 385(12): 1091 – 1103. Supplementary appendix.

Die Pflichtangaben finden Sie hier oder über den QR-Code:

[https://www.novartis.com/de-de/sites/novartis\\_de/files/427273\\_BT\\_Pluvicto.pdf](https://www.novartis.com/de-de/sites/novartis_de/files/427273_BT_Pluvicto.pdf)



418515 | Stand: 03/2024

 **PLUVICTO®**  
(<sup>177</sup>Lu)Lutetiumvipivotidtraxetan  
INJEKTIONS-/INFUSIONS-LÖSUNG

**DAY 1: SBRT** FRIDAY 19<sup>TH</sup> JULY 2024

**09.00-09.05** **Opening Remarks** | Anca-L. Grosu & Simon Spohn

**SBRT I - PRIMARY PROSTATE CANCER I**

Chair: Anca-L. Grosu and Michael Zelefsky

09.05-09.30 From Imaging to Biology for Radiation Treatment Planning in Prostate Cancer | Anca-L. Grosu

09.30-09.55 Hypofractionation in Lymph Node Positive Prostate Cancer | Thomas Zilli

09.55-10.20 Dose escalation in SBRT – what is the right dose? | Michael Zelefsky

10.20-10.45 SBRT – the Patients Perspective | Guenther Carl

**10.45-11.15** **Coffee Break and Poster Session**

**SBRT I - PRIMARY PROSTATE CANCER II**

Chair: Stefanie Corradini and Matthias Guckenberger

11.15-11.40 MRI-based Focal Dose Escalation (FLAME/HypoFlame trials) | Karin Haustermans

11.40-12.05 HypoFocal trials: MRI- and PSMA-PET-based Focal Dose Escalation | Simon Spohn

12.05-12.30 The Role of Brachytherapy in the Era of SBRT and focal dose escalation | Constantinos Zamboglou

**12.30-13.30** **Lunch + Industry Exhibition**

**SBRT II - RECURRENT AND METASTATIC PCA I**

Chair: Constantinos Zamboglou and Karin Haustermans

13.30-13.55 PSMA-PET for RTx in Recurrent Prostate Cancer | Nina Schmidt-Hegemann

13.55-14.20 Dose Escalation in Salvage Radiotherapy | Tobias Hölscher

14.20-14.45 Hypofractionation in Radiotherapy after Radical Prostatectomy | Stefano Arcangeli

**14.45-15.15** **Coffee Break and Poster Session**

**SBRT II - RECURRENT AND METASTATIC PCA II**

Chair: Thomas Zilli and Simon Kirste

15.15-15.40 Re-Irradiation EBRT | Giulia Marvaso

15.40-16.05 Brachytherapy in Recurrent Disease | Michael Pinkawa

16.05-16.30 Optimal Treatment for Nodal Oligorecurrent Prostate Cancer | Matthias Guckenberger

16.30-16.55 SBRT in Oligometastatic Prostate Cancer | Simon Lo

**17.00-17.30** **Visit of the Department of Radiation Oncology Freiburg** | Simon Spohn and Andreas Rimner

**19:00 - CONFERENCE DINNER** Greiffenegg Restaurant, Freiburg

**DAY 2: ADVANCES IN SYSTEMIC TREATMENT AND NEW TECHNOLOGIES** SATURDAY 20<sup>TH</sup> JULY 2024

**ADVANCES IN SYSTEMIC TREATMENT**

Chair: Cornelius Waller and Stefano Arcangeli

09.00-09.25 Androgendeprivation Therapy in Localized Prostate Cancer – Optimal Treatment and Management of Side Effects | Markus Grabbert

09.25-09.50 Systemic Treatment in Metastatic Prostate Cancer: Update on New Hormonal Agents and PARP-Inhibitors | Christian Gratzke

09.50-10.15 PSMA-targeted Radioligand Therapy – Updates in Tracer Development and Future Directions | Ann-Christin Eder

**10.15-10.45** **Coffee Break and Poster Session**

**NEW TECHNOLOGIES I: FUTURE PERSPECTIVES OF AI**

Chair: Stefanie Corradini and Matthias Guckenberger

10.45-11.05 AI-assisted MRI – Next Generation Imaging | Johannes Jahn

11.05-11.25 Automated Segmentation in Prostate Cancer | Tobias Fechter

11.25-11.45 Radiomics - New Possibilities for Prostate Cancer? | Jan Peeken

11.45-12.05 Histopathology- and AI-based Biomarkers | Christoph Schell

12.05-12.25 Proteomics in Prostate Cancer – A Novel Stratification Tool? | Oliver Schilling

**12.25-13.30** **Lunch + Industry Exhibition**

**NEW TECHNOLOGIES II: RADIOTHERAPY AND ADVANCED IGRT**

Chair: Simon Spohn and Tobias Hölscher

13.30-13.55 Adaptive Radiotherapy using the ETHOS System – Advances and Futures perspectives | Dimos Baltas

13.55-14.20 Adaptive Radiotherapy using MR Linacs | Stefanie Corradini

14.20-14.45 New Options for Intrafractional Tracking at the LINAC | Ute Ganswindt

**14.45-15.00** **Closing Remarks** | Anca-L. Grosu & Simon Spohn

## SOCIAL EVENING

July 19<sup>TH</sup>, 19:00h  
Restaurant Greiffenegg-Schlössle  
Schlossbergring 3 – Freiburg



## SPEAKERS & CHAIRS

**Prof. Dr. Stefano Arcangeli**

**Prof. Dr. Dimos Baltas**

**Ernst-Günther Carl**

**Prof. Dr. Stefanie Corradini**

**Dr. Ann-Christin Eder**

**Dr. Tobias Fechter**

**Prof. Dr. Ute Ganswindt**

**PD Dr. Markus T. Grabbert**

**Prof. Dr. Christian Gratzke**

**Prof. Dr. Anca-L. Grosu, FACR**

**Prof. Dr. Matthias Guckenberger**

**Prof. Dr. Karin Haustermans**

**Dr. Tobias Hölscher**

**Johannes Jahn**

**Dr. Simon Kirste**

**Prof. Simon S. Lo, FACR, FASTRO**

**Dr. Giulia Marvaso**

**PD Dr. Jan Peeken**

**Prof. Dr. Michael Pinkawa**

**Dr. Andreas Rimner**

**Prof. Dr. Dr. Christoph Schell**

**Prof. Dr. Oliver Schilling**

**PD Dr. Nina Schmidt-Hegemann**

**PD Dr. Simon Spohn**

**Prof. Dr. Cornelius Waller**

**PD Dr. Constantinos Zamboglou**

**Prof. Dr. Michael Zelefsky**

**Prof. Dr. Thomas Zilli**

University of Milan - Bicocca (IT)

Medical Center - University of Freiburg

Federal Association Prostate Cancer Self-Help BPS Bonn

LMU University Hospital Munich

Medical Center - University of Freiburg

Medical Center - University of Freiburg

University Medical Center, Innsbruck (AT)

Medical Center - University of Freiburg

Medical Center - University of Freiburg

Medical Center - University of Freiburg

University Hospital Zurich (CH)

University Medical Center, Leuven (BE)

University Medical Center, Dresden

Medical Center - University of Freiburg

Medical Center - University of Freiburg

UW Medical Center, Seattle WA (USA)

European Institute of Oncology IRCCS, Milan (IT)

TUM University Hospital Munich

Robert Janker Hospital Bonn

Medical Center - University of Freiburg

Medical Center - University of Freiburg

Medical Center - University of Freiburg

LMU University Hospital Munich

Medical Center - University of Freiburg

Medical Center - University of Freiburg

Medical Center - University of Freiburg and GOC (CY)

Perlmutter Cancer Center, New York NY (USA)

EOC Cantonal Hospital Bellinzona (CH)

## SPONSORS



## DISCLOSURE OF SPONSORSHIPS

**Astellas Pharma GmbH** – 2.000€

**Bayer Vital GmbH** – 1.000€

**Boston Scientific Limited** - 2.000€

**Brainlab Sales GmbH** – 2.000€

**C-RAD GmbH** – 500€

**Eckert & Ziegler BEBIG GmbH** – 1.000€

**Janssen-Cilag GmbH** – 750€

**Limbus AI Inc.** – 2.000€

**Naslund Medical AB (Golden Anchor)** – 2.000€

**Novartis Radiopharmaceuticals GmbH** - 3.500€

**PTW Freiburg GmbH** - 500€

**Unger Medizintechnik GmbH & Co. KG** – 2.000€

\*for advertising purposes

\*\*for a 4 sqm booth + advertising purposes

\*\*\*for a 8 sqm booth + advertising purposes

**NOTES**

A series of horizontal dotted lines for taking notes, consisting of approximately 30 lines.

Organized by the

**DEPARTMENT OF RADIATION ONCOLOGY**  
**Medical Center - University of Freiburg**

**Anca-Ligia Grosu, MD**

Medical Director, Department of Radiation Oncology

**Simon Spohn, MD**

**Conference Organizer: Elke Bühler**

+49 (0)761 270-19210

veranstaltung@uniklinik-freiburg.de


**Conference Venue:**

Lecture Hall – Department of Gynaecology

Medical Center - University of Freiburg

Hugstetter Str. 55, 79106 Freiburg

[www.uniklinik-freiburg.de/prostate-cancer-symposium.html](http://www.uniklinik-freiburg.de/prostate-cancer-symposium.html)



Published by: Medical Centre - University of Freiburg ©2024

Editors: Department of Radiation Oncology

Layout: Media centre | Medical Center - University of Freiburg